Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jep. Fa sho!! First fight in a while...so wouldnt have bet...weny byname recogniyion and feeling bad that McGregor got his arse whooped my Mayweather. Had no real horse in Saturday's game.
Anyone know if PLSB is doing...or planning to do CBD?
With you there.
Nice call. Didn't see that you put it out there earlier. Interested in seeing what it does in the AM!
Good eye there on GTXI M1999!!!
$VXRT News!
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxarts Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Business Wire "Press Releases - English"
Vaxart oral tablet vaccine provided 39% reduction in flu illness
compared to 27% for Fluzone
Strong 7+ plasmablasts response in Vaxart
vaccinees was highly correlated with protection
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vaxart, Inc., a clinical-stage biotechnology company developing oral
recombinant vaccines that are administered by tablet rather than by
injection, announced it will present new data from the Phase 2 Challenge
Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San
Francisco on Saturday, October 6, 2018.
These latest results show that our vaccine elicited a significant
expansion of mucosal homing receptor 47+ (7+)
plasmablasts to approximately 60% of all activated B cells, while
Fluzone only maintained baseline levels of 20%. We believe these 7+
plasmablasts are a key indicator of a protective mucosal immune response
and a unique feature of our oral recombinant vaccines, said Sean Tucker
Ph.D., chief scientific officer of Vaxart. Further analysis of the data
also confirm that, while our vaccine also generated protective
hemagglutinin inhibition (HAI) antibodies in serum like conventional
injectable flu vaccines, it primarily protected through the mucosal
mechanism, providing a robust 39% reduction in illness versus placebo
overall. In contrast, Fluzone, the market-leading injectable
quadrivalent influenza vaccine, only provided a 27% reduction in illness
versus placebo, while protecting primarily through HAI antibodies.
Vaxart previously reported only 37% of study participants receiving the
Vaxart vaccine developed influenza infection after challenge, compared
to 44% of those receiving Fluzone and 71% of those receiving placebo.
The new Phase 2 data to be presented at IDWeek 2018 showed that the
Vaxart vaccine generated a strong increase in mucosal homing antibody
secreting cells, or 7+ plasmablasts. In protected study
participants, the percentage of 7+ plasmablasts in
recipients of the Vaxart vaccine nearly doubled, whereas the percentage
of 7+ plasmablasts in Fluzone recipients remained unchanged.
In all our studies to date, we have seen both systemic and mucosal
immune responses, and this latest data provides solid evidence that our
vaccines indeed protect through mucosal immunity, the first line of
defense against mucosal infections, said Wouter Latour, M.D., chief
executive officer of Vaxart. We believe this clearly differentiates our
oral vaccines from conventional injectable vaccines, and strongly
suggests that vaccines based on Vaxarts proprietary vector adjuvant
system could be optimal to protect against mucosal pathogens, including
some of the major public health threats such as flu, norovirus, RSV and
many others.
The Phase 2 study was completed with support from Biomedical Advanced
Research and Development Authority (BARDA). Vaxart received a $13.9
million contract from BARDA in September 2015 to support the advanced
development of more effective influenza vaccines to ultimately improve
seasonal and pandemic influenza preparedness. The contract was increased
to $15.7 million in 2017.
The project has been funded in whole or in part with federal funds from
the Department of Health and Human Services Office of the Assistant
Secretary for Preparedness and Response; Biomedical Advanced Research
and Development Authority under Contract No. HHSO100201500034C.
About Influenza
The flu is a contagious respiratory illness caused by influenza viruses
that infect the nose, throat and sometimes the lungs. It can cause mild
to severe illness, and at times, can lead to death. While the impact of
flu varies, it places a substantial burden on the health of people in
the United States. The U.S. Centers for Disease Control and Prevention
(CDC) estimates that influenza has resulted in between 9.2 million and
60.8 million illnesses, between 140,000 and 710,000 hospitalizations and
between 12,000 and 56,000 deaths annually since 2010. For further
information on influenza, its burden on human health and vaccine
development, please visit the CDC website at www.cdc.gov/flu/.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxarts vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may also be useful for the treatment of chronic viral
infections and cancer. Vaxarts vaccines are administered using a
convenient room temperature-stable tablet, rather than by injection.
Vaxart believes that tablet vaccines are easier to distribute and
administer than injectable vaccines, and have the potential to
significantly increase vaccination rates. Vaxarts development programs
include oral tablet vaccines that are designed to protect against
norovirus, seasonal influenza and respiratory syncytial virus (RSV), as
well as a therapeutic vaccine for human papillomavirus (HPV). For more
information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
believe, could, potential, will and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxarts ability to develop and
commercialize its product candidates, clinical results and trial data,
Vaxarts ability to obtain and maintain regulatory approval of its
product candidates and Vaxarts reliance on third party funding and
grants. Vaxart may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that Vaxart makes, that Vaxarts product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S. regulatory
authorities, Vaxarts product candidates may not achieve broad market
acceptance; and the risks described in the Risk Factors sections of
the Registration Statement on Form S-4 (file no. 333-222009) and of
Vaxarts periodic reports filed with the SEC. Vaxart does not assume any
obligation to update any forward-looking statements, except as required
by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181004005175/en/
Carl Mauch
Stern Investor Relations
212-362-1200
vaxart@sternir.com
Source: Vaxart, Inc.
Should have sold? Why? Because of the shake and bake? That was designed to frighten. Someone's accumulating this bigly...hoping for some of the more timid to dump.
Company already raised needed funds in anticipation of a scenario like this. $162mil cash on hand as a result.
Where you been man?
Looks like another green day. Sorry newbs!!! LoLzzz
$NBEV
Peeps don't always read carefully...or 'between the lines' for that matter. Wouldn't be surprised to see a .05 or .06 open tomorrow.
Smash-party going on!! lolzzz
$HMNY
PTIE!! Holy chit! Tried and did!!
Sweet close!! Game still on here! $NBEV
Jep! Nice alert there on HMNY!
Unreal! Markets are loving these upper-tier plays trading under .20. I would think the AH session in HMNY is going to be sick!
NVCN - They also recently did an RS so I would think the current float is nice and tight!
VTVT!! Nice!! Waiting for GERN to pull a move like that. Meanwhile...NBEV...green!! PTIE - trying.
You can't have missed it if it just started trading on the Canadian Exchange. This is an IPO...you're currently on the ground floor here my man.
Food for thought!
Night bro. Let's shoot for a reply of today, tomorrow!!
Alwsys happy to have new and familiar faces. Team effort helps ensure we get those alerts out on the board...and 'Team' meams all of you guys too!!
Next to go!
$GERN
Living up to the hype!!
$OGEN
Looking that way. Volume spiking into the close here. Hmmmm....
$GERN
GERN - Getting accumulated thid morning. $1.67 now! Triple bottom.
Sweet alert on HIPH there HB!!!
Just getting started baby-girl!!
MMs not giving up shares. Hard to get my orders filled. Argh!!!
$CZNI
Jep!! When you consider the $700mil in dollar trading volume and the YUGE relative-to-daily trading volume today, NBEV closed at the HOD...so it still has not topped out. Not sure what the shorts working to take this down at the end of the AH session were thinking. Geesh!
Tomorrow should be a sweet day fa-sho!!
Thanks FB. That's the answer I was looking for!!
Q for the board...will peeps be able to trade their shares right away or will they be locked pending the brokerages getting clearance to convert the UHLN shares to the new ticker? Curious...sorry if this has already been put out there. Catching up on my 'daily briefing'.
Thanks in advance.
New 52-week high!!!! Weeeeeeeee!!!!!
Oh chit!!! Here comes 10s!!!!!!!!
$NBEV
The BIG FAT squeeze is on in the AH session!!! Boom!
$NBEV
Well...the best part about NBEV is that it corrected from last week Friday (Sept. 21st through 27th)...so this is going to be on some rocket-fuel this week.
Just sayin. You can go and consult the charts if you'd like.
Just in case peeps missed this post earlier: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143710550
...and it doesn't stop there. Keep in mind that NBEV is not running simply on their event that starts tomorrow...else IGC and TLRY would not be running in tandem as they have no event slated for this week. The sector is HIT HOT HOT and we're jest starting to rev.
Buy and hold here peeps. Don't get shook for your shares!!
8sssssss!!!! Weeeeeee!!!
$IGC
Uh oh shorties!!
$NBEV